ArticleScientific reports2025
A mitochondrial-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anticancer Effect of Pacificusoside D from the StarfishMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, characterized by frequent recurrence and poor clinical outcomes. This study aimed to develop a mitochondria-related genes (MRGs) signature for prognostic stratification and immunotherapy response prediction in HCC patients. Derived from the TCGA-LIHC cohort and validated across independent ICGC-JP and GEO datasets, the MRGs signature comprised four genes (DTYMK, ABCB6, GOT2, and TOMM40L) that were markedly overexpressed in HCC tissues and strongly associated with adverse prognosis. MRGs-based nomogram exhibited superior predictive accuracy, highlighting their clinical potential for personalized risk assessment. Within the tumor microenvironment, high-MRGs tumors demonstrated significant enrichment of immunosuppressive components, including regulatory T cells, tumor-associated macrophages, and checkpoint molecules PD-1 and CTLA-4. The MRGs-high subgroup showed heightened sensitivity to cisplatin but resistance to erlotinib, and impaired immunotherapy responses, which has potential clinical transformation value in the design of individualized combination therapy. Functional validation revealed ABCB6 as a key oncogenic driver, with genetic depletion significantly attenuating HCC cell proliferation, migration, and invasion in vitro. Collectively, the MRGs signature serves as a better predictor of HCC prognosis and therapeutic resistance, while its core component ABCB6 emerges as a critical regulator of HCC malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.